External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ISPOR EU 2024
Roche and Genentech at

ISPOR EU 2024

November 17 - November 20
Barcelona, Spain
ispor.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 20 / Roche
Utility Analysis of Crovalimab▼ and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Haematology Paroxysmal Nocturnal Hemoglobinuria ISPOR-EUROPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 19 / Roche and Genentech
Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH)▼ + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data from the 8.4-Year Follow-Up of APHINITY
The randomised, global, Phase III APHINITY trial assessed the addition of pertuzumab to trastuzumab▼ and chemotherapy for the adjuvant treatment of HER2-positive early breast cancer. A previous cost-effectiveness analysis model used primary analysis data from APHINITY to project cost-effectiveness of pertuzumab plus trastuzumab▼-based therapy in the US; the current poster reports an updated cost-effectiveness analysis model with data from the third interim analysis of APHINITY in three countries (Belgium, Spain and the Republic of Ireland), along with an exploration of how changes in the metastatic breast cancer treatment landscape can impact the results of the early breast cancer model.
Oncology Breast Cancer ISPOR-EUROPE-2024

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Nov 19 / Roche
Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry
WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.
Oncology HealthTech Next Generation Sequencing ISPOR-EUROPE-2024
08:00 AM
Duration 3hrs Barcelona, Spain
Cost Consequence Analysis of Using the Elecsys Anti-Müllerian Hormone Plus Immunoassay as Part of Polycystic Ovary Syndrome Assessment in the United Kingdom
Osvaldo Ulises Garay, Anna-Maria Olziersky, Joop Laven, Rebecca Mawson, Terhi Piltonen, Stephen Franks, Johanna Sillman
Gynaecology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 3hrs Barcelona, Spain
Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry
Rodrigo Dienstmann
Oncology - HealthTech

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3hrs Barcelona, Spain
Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data from the 8.4-Year Follow-Up of APHINITY
Svenn A. Kommandantvold, Matthieu J. Schlögel, Lucia Ruiz de Alda, Siobhán Browne
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:00 AM
Duration 150mins Barcelona, Spain
Utility Analysis of Crovalimab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Christian Bührer
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.